Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. Stock Forecast & Price Prediction

Live Ginkgo Bioworks Holdings, Inc. Stock (DNA) Price
$8.31

2

Ratings

  • Buy 0
  • Hold 0
  • Sell 2
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$8.31

P/E Ratio

-0.45

Volume Traded Today

$841,300

Dividend

Dividends not available for DNA

52 Week High/low

75.20/5.26

Ginkgo Bioworks Holdings, Inc. Market Cap

$435.7M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $DNA ๐Ÿ›‘

Before you buy DNA you'll want to see this list of ten stocks that have huge potential. Want to see if DNA made the cut? Enter your email below

DNA Summary

From what 2 stock analysts predict, the share price for Ginkgo Bioworks Holdings, Inc. (DNA) might increase by 5.9% in the next year. This is based on a 12-month average estimation for DNA. Price targets go from $7 to $10. The majority of stock analysts believe DNA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

DNA Analyst Ratings

About 2 Wall Street analysts have assigned DNA 0 buy ratings, 0 hold ratings, and 2 sell ratings. This means that analysts expect Ginkgo Bioworks Holdings, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on DNA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

DNA stock forecast by analyst

These are the latest 20 analyst ratings of DNA.

Analyst/Firm

Rating

Price Target

Change

Date

Brendan Smith
TD Cowen

Buy

$10

Maintains

Sep 20, 2024
Mark Massaro
BTIG

Sell

$7

Maintains

Aug 23, 2024
Matthew Sykes
Goldman Sachs

Sell

$0.3

Maintains

Jul 9, 2024
Mark Massaro
BTIG

Sell

$0.2

Maintains

Jun 26, 2024
Mark Massaro
BTIG

Sell


Downgrade

May 15, 2024
Tejas Savant
Morgan Stanley

Equal-Weight

$1

Maintains

May 15, 2024
Matt Larew
William Blair

Underperform


Downgrade

May 10, 2024
Steven Mah
TD Cowen

Outperform

$3

Maintains

Mar 1, 2024
Matthew Sykes
Goldman Sachs

Sell

$1.1

Maintains

Jan 23, 2024
Matthew Sykes
Goldman Sachs

Sell

$1.1

Maintains

Jan 22, 2024
Rahul Sarugaser
Raymond James

Market Perform

$2.5

Downgrade

Nov 15, 2023
Rahul Sarugaser
Raymond James

Market Perform

$2.5

Downgrade

Nov 14, 2023
Mark Massaro
BTIG

Neutral


Downgrade

Nov 9, 2023
Matthew Sykes
Goldman Sachs

Sell

$1.25

Maintains

Jun 5, 2023
Matthew Sykes
Goldman Sachs

Sell

$1.25

Downgrade

Jun 2, 2023
Matt Larew
William Blair

Market Perform


Downgrade

May 11, 2023
Gaurav Goparaju
Berenberg

Buy

$6

Initiates

Nov 29, 2022
Tejas Savant
Morgan Stanley

Equal-Weight

$5

Initiates

Oct 4, 2022
Mark Massaro
BTIG

Buy

$6

Maintains

Aug 16, 2022
Rahul Sarugaser
Raymond James

Outperform

$14.5

Maintains

Aug 16, 2022

DNA Company Information

What They Do: Develops cell programming platforms for biological production.

Business Model: The company utilizes its cell programming platform to enable the production of a variety of biological products, including therapeutics, food ingredients, and petrochemical-derived chemicals. It generates revenue by serving various industries such as pharmaceuticals, biotechnology, agriculture, and government sectors, providing tailored solutions to meet their specific needs.

Other Information: Founded in 2008 and headquartered in Boston, Massachusetts, the company is positioned at the intersection of biotechnology and technology, catering to a diverse range of sectors, which may provide it with significant growth opportunities as demand for biological products increases.
DNA
Ginkgo Bioworks Holdings, Inc. (DNA)

When did it IPO

2021

Staff Count

1,218

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Jason Kelly

Market Cap

$435.7M

Ginkgo Bioworks Holdings, Inc. (DNA) Financial Data

In 2023, DNA generated $251.5M in revenue, which was a decrease of -47.36% from the previous year. This can be seen as a signal that DNA's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$76.7M

Revenue From 2021

$313.8M

309.40 %
From Previous Year

Revenue From 2022

$477.7M

52.21 %
From Previous Year

Revenue From 2023

$251.5M

-47.36 %
From Previous Year
  • Revenue TTM $184.3M
  • Operating Margin TTM -274.5%
  • Gross profit TTM $197.5M
  • Return on assets TTM -22.3%
  • Return on equity TTM -76.8%
  • Profit Margin 78.5%
  • Book Value Per Share 16.03%
  • Market capitalisation $435.7M
  • Revenue for 2021 $313.8M
  • Revenue for 2022 $477.7M
  • Revenue for 2023 $251.5M
  • EPS this year (TTM) $-18.00

Ginkgo Bioworks Holdings, Inc. (DNA) Latest News

News Image

Tue, 05 Nov 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Ginkgo Bioworks will host a Q&A session on November 12, 2024, at 5:30 p.m. ET to discuss its Q3 2024 business performance. Details will be on their investor relations website.

Why It Matters - The upcoming presentation on Ginkgo Bioworks' Q3 performance will provide insights into its financial health and strategic direction, impacting investor sentiment and stock valuation.

News Image

Mon, 04 Nov 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.63, down 1.55% from the previous trading day.

Why It Matters - The decline in Ginkgo Bioworks' stock price signals potential investor concern, which might affect future trading and investment strategies.

News Image

Wed, 09 Oct 2024

Sentiment - NEGATIVE

Source - GuruFocus

Summary - Ginkgo Bioworks' stock fell 5.04% to $7.92 with a trading volume of 354,386 shares and a price fluctuation of 6.59%. Turnover rate was 0.64%.

Why It Matters - Ginkgo Bioworks' 5.04% stock drop and high volatility indicate potential investor concerns, impacting market sentiment and signaling possible risks in its financial health.

News Image

Thu, 03 Oct 2024

Sentiment - NEUTRAL

Source - Business Wire

Summary - Virica and Ginkgo have formed a strategic partnership to improve the productivity of adeno-associated virus (AAV) gene therapy manufacturing platforms.

Why It Matters - The partnership between Virica and Ginkgo could lead to improved AAV gene therapy production, potentially increasing market competitiveness and influencing biotech stock valuations.

News Image

Thu, 26 Sep 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.70, down 0.77% from the previous trading day.

Why It Matters - Ginkgo Bioworks' recent stock decline indicates potential volatility, impacting investor sentiment and future trading strategies.

News Image

Tue, 24 Sep 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - Ginkgo Bioworks (NYSE: DNA) announced a partnership with NOVUS International to develop advanced feed additives for the animal agriculture industry.

Why It Matters - Ginkgo Bioworks' partnership with NOVUS International indicates growth potential in the animal agriculture sector, potentially enhancing revenue and market position for both companies.

...

DNA Frequently asked questions

The highest forecasted price for DNA is $10 from Brendan Smith at TD Cowen.

The lowest forecasted price for DNA is $7 from Mark Massaro from BTIG

The DNA analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 2 sell ratings.